Technical setup takes shape after early August sell off

TG Therapeutics (TGTX) is back in focus after the stock formed a cup style base following a sell off in early August, with shares now testing a key moving average.

This type of technical setup often interests traders who follow price patterns. It can highlight areas where buying and selling pressure may be starting to rebalance after a sharp move.

For context, TG Therapeutics has seen strong momentum build over the past year, with a 1 day share price return of 3.21%, a 7 day share price return of 13.66% and a year to date share price return of 91.29%, while the 1 year total shareholder return is 96.32% and the 3 year total shareholder return is more than 4x.

If you are looking beyond TG Therapeutics for other high growth stories in healthcare, this is a good moment to check out 40 healthcare AI stocks

Bulls point to TG Therapeutics’ strong recent returns, as well as its revenue and net income growth. Bears focus on biotech risk and how much is already in the price. Which side do the current valuation markers support next?

Most Popular Narrative: 8% Overvalued

The most followed narrative puts TG Therapeutics’ fair value at $51.71, compared with the last close at $56.01. This frames the recent strength in a different light.

The analysts have a consensus price target of $51.71 for TG Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.

Given the current share price of $53.22, the analyst price target of $51.71 is 2.9% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.

Want to see why this narrative still sees only modest upside from here? The key moving pieces are revenue expansion, margin compression and a reset on the future earnings multiple.

Result: Fair Value of $51.71 (OVERVALUED)

However, TG Therapeutics still faces key risks if BRIUMVI loses share to rival MS therapies or if reimbursement pressure squeezes pricing and margins.

Another View: TG Therapeutics Through A P/E Lens

The first narrative around TG Therapeutics leans on analyst fair value at $51.71. On simple P/E maths, the picture is different. At 18x earnings, the stock is slightly above the US Biotechs average of 17.8x, yet below an estimated fair ratio of 25.7x, which points to both valuation risk and potential re rating room. Which signal do you put more weight on: current market pricing, or where the fair ratio suggests the multiple could drift over time?

For a closer look at what these P/E gaps might mean in practice, check the detailed valuation breakdown in See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals around TG Therapeutics in this article, it makes sense to look at the numbers yourself and weigh both sides. To see how the balance of risk and reward currently stacks up, start with the 3 key rewards and 1 important warning sign.

Looking for more TG Therapeutics style investment ideas?

If you are serious about building a stronger watchlist beyond TG Therapeutics, now is the time to scan for other opportunities before the next move happens.

• Spot potential turnaround candidates early by running through 22 elite penny stocks with strong financials while they still fly under most investors' radar.
• Strengthen your core holdings by searching for companies in the solid balance sheet and fundamentals stocks screener (51 results) that might handle pressure better than the broader market.
• Hunt for fresh opportunities by reviewing the screener containing 18 high quality undiscovered gems before the crowd starts paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.